+44 20 3868 9735
Scientific Tracks Abstracts: J Glycobiol
The O-GlcNAc transferase (OGT) is a key regulator of the post-translational modification of proteins by O-linked β-Nacetyl
glucosamine (O-GlcNAc) onto Ser/Thr residues. OGT uses the end product of the hexosamine biosynthetic pathway
(HBP), UDP-GlcNAc, as a donor for O-GlcNAcylation processes. It is reported that OGT and O-GlcNAcylation levels are
increased in cancers. We showed that in the colorectal cancers (CRC) cell lines (HT29, HCT116) the expression of OGT and
O-GlcNAcylation level were elevated and that O-GlcNAcylation directly interfered with β-catenin stability and proliferation of
cells. Previous studies showed that oncogenic factors such as p53, MYC or β-catenin are O-GlcNAcylated. The Wnt/β-catenin
pathway is modified in most CRC by genetic alteration of β-catenin or one member of the destruction complex. Consequently,
β-catenin is protected from proteasomal degradation and therefore induces cell proliferation. A similar observation was
made when HBP flux was increased by culturing cells in high glucose medium. In these conditions, ï¢-catenin was protected
against the degradation thus accelerating cell proliferation. In a recent study, we identified four O-GlcNAcylation sites at the
N-terminus of β-catenin, one of those (T41) localized in the destruction box is crucial for the control of β-catenin degradation.
In that context we studied the effect of OGT silencing in CRC cell lines and non cancer cell line CCD841CoN. We reported that
silencing of OGT halved proliferative and migratory capacities of cancer cells. OGT knock-down also diminished cell adhesion
corroborating previous observations that inhibiting O-GlcNAcylation decreases β-catenin/α-catenin interactions necessary
for mucosa integrity which suggests that O-GlcNAcylation also affects localization of ï¢-catenin at adherens junction level.
Agata Steenackers defended her PhD thesis in the field of Biology and Biotechnologies in November 2013 at the Lille 1 University (France). During her PhD, she
developed a project around the expression of GD3 synthase and gangliosides in breast cancer cells lines. She is now on a Post-doctoral position in Tony Lefebvre’s
team (UGSF) where she is studying the role of O-GlcNAcylation in colon cancer development.